A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML

COVALENT-103: investigating BMF-500, an oral covalent FLT3 inhibitor, in acute leukemiasПодробнее

Phase III trial of azacitidine and gilteritinib in FLT3 mutant AMLПодробнее

Phase I/II study of novel FLT3 inhibitor HM43239 in R/R AMLПодробнее

The value of FLT3 inhibitors in AML and focus for future trial designsПодробнее

FF-10101-01: a novel FLT3 inhibitor for R/R AMLПодробнее

Novel FLT3 inhibitors for AMLПодробнее

Role of FLT3 Inhibitors and Other Novel Agents in AMLПодробнее

Novel potent and selective FLT3 inhibitorsПодробнее

A Phase I study of CPX-351 plus gilteritinib in R/R FLT3-mutated AMLПодробнее

Novel treatment combinations for FLT3-mutated AMLПодробнее

Finding the Key to Better Outcomes in FLT3-Mutated AMLПодробнее

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with flt3-mutated re...Подробнее

Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AMLПодробнее

Developing novel FLT3 inhibitor by Jenna DoranПодробнее

Improving outcomes for FLT3-mutated R/R AMLПодробнее

The use of FLT3 inhibitors in AMLПодробнее

FLT3 inhibitor maintenance after allo-SCT for AMLПодробнее

Race to World First 11.1 - Liberation of Undermine - Day 5Подробнее

Randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AMLПодробнее